Literature DB >> 8436337

Molecular differential pathology of renal cell tumours.

G Kovacs1.   

Abstract

Recent application of molecular cytogenetic techniques to the evaluation of renal cell tumours revealed four subtypes, each with a characteristic combination of genetic alterations within the chromosomal and mitochondrial DNA. The most common, nonpapillary renal cell carcinomas are characterized by the loss of chromosome 3p sequences, rearrangement of the chromosome 5q region and loss of the chromosome 14q sequences. Papillary renal cell tumours can be divided into two groups. Tumours with a combined trisomy of chromosomes 7 and 17 as well as loss of the Y chromosome are papillary renal cell adenomas. Tumours with additional trisomies such as trisomy 16, 20 or 12 are papillary renal cell carcinomas. Chromophobe renal cell carcinomas show a combination of allelic losses, which do not occur in other types of renal tumours. In addition, they have a rearrangement in the mitochondrial DNA. Renal oncocytomas are benign tumours marked by normal or abnormal karyotypes with balanced or unbalanced translocations and an altered restriction pattern of the mitochondrial DNA. Although the major cytological characteristics of renal cell tumours, such as clear, granular, chromophobe and oncocytic cell phenotypes correspond to nonpapillary, papillary and chromophobe renal cell carcinomas and renal oncocytomas, there are many cases with overlapping phenotype. Therefore, a classification of renal cell tumours based on specific genetic alterations is proposed.

Entities:  

Mesh:

Year:  1993        PMID: 8436337     DOI: 10.1111/j.1365-2559.1993.tb00061.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  20 in total

1.  Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization.

Authors:  M R Speicher; B Schoell; S du Manoir; E Schröck; T Ried; T Cremer; S Störkel; A Kovacs; G Kovacs
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

Review 2.  Genetic predisposition to kidney cancer.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

3.  Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.

Authors:  G Chemeris; A Loktinov; A Rempel; M Schwarz; P Bannasch
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma.

Authors:  Gábor Cserni; Beáta Rita Kovács; Miklós Tarján; Zoltán Sápi; Zsolt Domján; Zoltán Szabó
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

5.  Proliferation kinetics of streptozotocin-induced renal tumours in mice.

Authors:  B Delahunt; P R Cartwright; A Thornton; P J Dady
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 6.  The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours.

Authors:  G Kovacs
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma.

Authors:  C D Gerharz; R Moll; S Störkel; U Ramp; B Hildebrandt; G Molsberger; P Koldovsky; H E Gabbert
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

8.  Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.

Authors:  H J Terpe; S Störkel; U Zimmer; V Anquez; C Fischer; K Pantel; U Günthert
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

Review 9.  Genomics of renal cell cancer-- does it provide breakthrough?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

10.  High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas.

Authors:  Maria V Yusenko; Roland P Kuiper; Tamas Boethe; Börje Ljungberg; Ad Geurts van Kessel; Gyula Kovacs
Journal:  BMC Cancer       Date:  2009-05-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.